bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

Maria Zannes, President and CEO of bioAffinity Technologies

“One of our objectives for 2026 is executing on our strategy to expand access and drive adoption of CyPath Lung with physicians who have used our test over time. We believe that sales of CyPath Lung in the third quarter of this year demonstrate the ongoing success of our efforts.”

Maria Zannes, President and CEO of bioAffinity Technologies

“The 100% increase in third-quarter sales reflects growing utilization of CyPath Lung in pulmonology and oncology practices, lung nodule clinics and community medical centers. As we continue to increase our marketing efforts, we believe we are well positioned to pursue similar results generated by a larger base of physician prescribers. We are especially focused on executing our new distribution agreement with Veteran-Owned AvMEDICAL, which we believe could help broaden our reach in the government healthcare system, including the Department of Veterans Affairs.”

Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies

“As clinicians, we are happy to see more eligible patients undergoing the recommended lung cancer screening. But as more nodules are identified by imaging, physicians increasingly need more information to help determine the appropriate next steps for individual patients.”

Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies

“CyPath Lung is designed to help fill that need by providing a result indicating either likely or unlikely malignancy in the lung, which can be considered alongside imaging, clinical history and other findings to help determine whether a patient is most likely to benefit from additional monitoring, further diagnostic evaluation or an invasive procedure.”